| Tonic B-cell receptor signaling in diffuse large B-cell lymphoma O Havranek, J Xu, S Köhrer, Z Wang, L Becker, JM Comer, J Henderson, ... Blood, The Journal of the American Society of Hematology 130 (8), 995-1006, 2017 | 118 | 2017 |
| Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer P Kleiblova, L Stolarova, K Krizova, F Lhota, J Hojny, P Zemankova, ... International journal of cancer 145 (7), 1782-1797, 2019 | 96 | 2019 |
| Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition S Köhrer, O Havranek, F Seyfried, C Hurtz, GP Coffey, E Kim, ... Leukemia 30 (6), 1246-1254, 2016 | 83 | 2016 |
| Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma D Prukova, L Andera, Z Nahacka, J Karolova, M Svaton, M Klanova, ... Clinical Cancer Research 25 (14), 4455-4465, 2019 | 78 | 2019 |
| Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs R Mathur, L Sehgal, O Havranek, S Köhrer, T Khashab, N Jain, JA Burger, ... Haematologica 102 (2), 373, 2017 | 69 | 2017 |
| Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma N Jain, K Hartert, S Tadros, W Fiskus, O Havranek, MCJ Ma, A Bouska, ... Science translational medicine 11 (497), eaav5599, 2019 | 61 | 2019 |
| B-cell receptor signaling regulates metabolism in chronic lymphocytic leukemia HV Vangapandu, O Havranek, ML Ayres, BA Kaipparettu, K Balakrishnan, ... Molecular Cancer Research 15 (12), 1692-1703, 2017 | 57 | 2017 |
| The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population Z Kleibl, O Havranek, I Hlavata, J Novotny, J Sevcik, P Pohlreich, ... European journal of cancer 45 (4), 618-624, 2009 | 52 | 2009 |
| Association of germline CHEK2 gene variants with risk and prognosis of non-Hodgkin lymphoma O Havranek, P Kleiblova, J Hojny, F Lhota, P Soucek, M Trneny, Z Kleibl PLoS One 10 (10), e0140819, 2015 | 47 | 2015 |
| Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations Z Kleibl, O Havranek, J Novotny, P Kleiblova, P Soucek, P Pohlreich Breast cancer research and treatment 112, 159-164, 2008 | 39 | 2008 |
| Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML S Herbrich, N Baran, T Cai, C Weng, MJL Aitken, SM Post, J Henderson, ... Journal for immunotherapy of cancer 9 (7), 2021 | 37 | 2021 |
| Targeting phosphatidylinositol 3 kinase-β and-δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma N Jain, S Singh, G Laliotis, A Hart, E Muhowski, K Kupcova, T Chrbolkova, ... Blood Advances 4 (18), 4382-4392, 2020 | 27 | 2020 |
| Inhibition of PIM kinases in DLBCL targets MYC transcriptional program and augments the efficacy of anti-CD20 antibodies M Szydłowski, F Garbicz, E Jabłońska, P Górniak, D Komar, B Pyrzyńska, ... Cancer Research 81 (23), 6029-6043, 2021 | 26 | 2021 |
| B-cell receptor signaling and beyond: the role of Igα (CD79a)/Igβ (CD79b) in normal and malignant B cells A Tkachenko, K Kupcova, O Havranek International Journal of Molecular Sciences 25 (1), 10, 2023 | 24 | 2023 |
| Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma O Havranek, M Spacek, P Hubacek, H Mocikova, J Markova, M Trneny, ... Neoplasma 58 (5), 392, 2011 | 19 | 2011 |
| CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer B Mohelnikova-Duchonova, O Havranek, I Hlavata, L Foretova, Z Kleibl, ... Cancer epidemiology 34 (5), 656-658, 2010 | 19 | 2010 |
| ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast … L Stolarova, P Kleiblova, P Zemankova, B Stastna, M Janatova, ... Clinical Cancer Research 29 (16), 3037-3050, 2023 | 17 | 2023 |
| Circulating tumor DNA in Hodgkin lymphoma M Maco, K Kupcova, V Herman, I Ondeckova, T Kozak, H Mocikova, ... Annals of Hematology 101 (11), 2393-2403, 2022 | 16 | 2022 |
| Anti-apoptotic MCL1 protein represents critical survival molecule for most Burkitt lymphomas and BCL2-negative diffuse large B-cell lymphomas M Klanova, D Kazantsev, E Pokorna, T Zikmund, J Karolova, M Behounek, ... Molecular Cancer Therapeutics 21 (1), 89-99, 2022 | 15 | 2022 |
| Assessing regulated cell death modalities as an efficient tool for in vitro nanotoxicity screening: a review A Tkachenko, A Onishchenko, V Myasoedov, S Yefimova, O Havranek Nanotoxicology 17 (3), 218-248, 2023 | 14 | 2023 |
Zdenek KleiblCharles University, First Faculty of Medicine & General University Hospital ♦ IMBLDVerified email at lf1.cuni.cz
